

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AZURITY PHARMACEUTICALS, INC.,
Petitioner,

v.

HELSINN HEALTHCARE S.A.,
Patent Owner.

Case No. IPR2025-00945
Patent No. 8,623,826

PETITIONER'S REQUEST FOR ORAL ARGUMENT

37 C.F.R. §42.70(a)

The petitioner (Azurity) requests oral argument regarding its challenge to the patentability of claims of U.S. Patent No. 8,623,826 and related issues that have been briefed.

Azurity requests an in-person hearing be held at the USPTO's Alexandria, Virginia office. Because the issues in all five inter partes reviews (IPR2025-00945 – IPR2025-00949) substantially overlap, Azurity requests no more than one hour of oral argument per side for all five IPRs together. The oral argument is currently scheduled to be held September 2, 2026, pursuant to Paper No. 13.

Respectfully submitted,

Dated: 8 July 2026

/Richard Torczon/

Richard Torczon, Reg. No. 34,448

Lead counsel for Azurity Pharmaceuticals

CERTIFICATE OF SERVICE

I certify that this paper was served today on Patent Owner at the following
electronic service addresses:

Eric W. Dittmann
Naveen Modi
Melanie R. Rupert
Isaac S. Ashkenazi
Chetan Bansal
Justin T. Fleischacker
PAUL HASTINGS LLP
ericdittmann@paulhastings.com
naveenmmodi@paulhastings.com
melanierupert@paulhastings.com
isaacashkenazi@paulhastings.com
chetanbansal@paulhastings.com
justinfleischacker@paulhastings.com
PH-Azurity-Helsinn-IPR@paulhastings.com

Respectfully submitted,

Dated: 08 July 2026

/ Yawen Wang /
Yawen Wang